News
OTLKW
0.0300
0.00%
0.00
OUTLOOK THERAPEUTICS ANNOUNCES PRICING OF $5.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
Reuters · 2d ago
Outlook Therapeutics director Randy H. Thurman reports purchase of 5,000 common shares for $2,145
PUBT · 3d ago
Outlook Therapeutics director Kurt J. Hilzinger acquires 400,000 common shares for $176,520
PUBT · 3d ago
BUZZ-Outlook Therapeutics jumps on plans to resubmit marketing application for eye disease treatment
Reuters · 5d ago
OUTLOOK THERAPEUTICS INC - TO RESUBMIT ONS-5,010/LYTENAVA BLA IN JUNE 2026
Reuters · 5d ago
OUTLOOK THERAPEUTICS INC - FDA GRANTS APPEAL FOR OUTLOOK THERAPEUTICS' ONS-5,010/LYTENAVA
Reuters · 5d ago
Outlook Therapeutics says FDA grants appeal on Lytenava effectiveness in nAMD review
PUBT · 5d ago
OUTLOOK THERAPEUTICS INC <OTLK.O>: BTIG CUTS TO NEUTRAL FROM BUY
Reuters · 05/18 10:45
Outlook Therapeutics Q2 adjusted EPS misses analyst expectations
Reuters · 05/15 20:17
Outlook Therapeutics FY26 Q2 net loss narrows to $4.45 million; revenue $128,000
PUBT · 05/15 20:06
OUTLOOK THERAPEUTICS INC - COMPLETES FDA DISPUTE RESOLUTION MEETING FOR ONS-5010; DECISION EXPECTED IN MAY 2026
Reuters · 05/15 20:05
OUTLOOK THERAPEUTICS INC - ENTERS SALES AGREEMENT WITH H.C. WAINWRIGHT TO OFFER AND SELL COMMON STOCK UP TO $100 MLN - SEC FILING
Reuters · 05/13 21:14
OUTLOOK THERAPEUTICS INC - TERMINATES ATM SALES AGREEMENT WITH BTIG EFFECTIVE MAY 12, 2026 - SEC FILING
Reuters · 05/13 20:42
Outlook Therapeutics inks $100 million at-the-market equity sales agreement with H.C. Wainwright
PUBT · 05/13 20:37
Outlook Therapeutics prices private placement warrants for 16,129,033 shares at $0.31
PUBT · 04/23 20:59
OUTLOOK THERAPEUTICS ANNOUNCES CLOSING OF $5.0 MILLION REGISTERED DIRECT OFFERING
Reuters · 04/23 20:05
Outlook Therapeutics issues unregistered warrants for 16,129,033 shares at $0.31 each
PUBT · 04/22 12:33
OUTLOOK THERAPEUTICS ANNOUNCES $5.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
Reuters · 04/22 12:30
Outlook Therapeutics completes FDA dispute resolution meeting over LYTENAVA approval path
PUBT · 04/21 13:06
BRIEF-Outlook Therapeutics Completes Federal Dispute Resolution (Fdr) Meeting With FDA For Ons-5010/Lytenava™ (Bevacizumab-Vikg)
Reuters · 04/21 13:05
More
Webull provides a variety of real-time OTLKW stock news. You can receive the latest news about Outlook Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About OTLKW
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.